Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome

Antonia M.W. Coppus, Maaike Schuur, Jeanet Vergeer, A. Cecile J.W. Janssens, Ben A. Oostra, Marcel M. Verbeek, Cornelia M. van Duijn

Research output: Contribution to journalArticleAcademicpeer-review

74 Citations (Scopus)


Extracellular deposition of amyloid beta peptide (Aβ) has been implicated as a critical step in the pathogenesis of Alzheimer's disease (AD). In Down syndrome (DS), Alzheimer's disease is assumed to be caused by the triplication and overexpression of the gene for amyloid precursor protein (APP), located on chromosome 21. Plasma concentrations of Aβ1-40 and Aβ1-42 were determined in a population based study of 506 persons with DS, who were screened annually for dementia. We used Cox proportional hazards models to determine the risk of dementia. Demented persons with DS have a significantly higher plasma Aβ1-40 concentration than the nondemented (p = 0.05). Those with the highest concentrations of Aβ1-40 and Aβ1-42 have a higher risk to develop dementia. The risk to develop dementia during follow-up (mean 4.7 years) increased to 2.56 (95% confidence interval, 1.39-4.71) for Aβ1-42 and 2.16 (95% confidence interval, 1.14-4.10) for Aβ1-40. High plasma concentration of plasma Aβ1-40 and Aβ1-42 are determinants of the risk of dementia in persons with DS.

Original languageEnglish
Pages (from-to)1988-1994
Number of pages7
JournalNeurobiology of aging
Issue number9
Publication statusPublished - Sept 2012


  • Abeta
  • Alzheimer's disease
  • Amyloid precursor protein
  • Down syndrome

Cite this